Polymorphisms in BRCA2 resulting in aberrant codon-usage and their analysis on familial breast cancer risk

  • Rongxi Yang
  • Bowang Chen
  • Kari Hemminki
  • Barbara Wappenschmidt
  • Christoph Engel
  • Christian Sutter
  • Nina Ditsch
  • Bernhard H. F. Weber
  • Dieter Niederacher
  • Norbert Arnold
  • Alfons Meindl
  • Claus R. Bartram
  • Rita K. Schmutzler
  • Barbara Burwinkel
Epidemiology

Abstract

Mutations in BRCA1 and BRCA2 are associated with increased breast cancer risk. While numerous non-synonymous SNPs in BRCA1/2 have been investigated for breast cancer risk, the impact of synonymous SNPs has not been studied so far. Recently, it has been reported that synonymous SNPs leading to an aberration from the preferred codon-usage can have functional effects and consequently be associated with disease. This motivated us to search for SNPs with the tendency to differential codon-usage in BRCA1/BRCA2. Based on defined criteria, two codon-usage-changing variants, Ser455Ser (1365A > G) and Ser2414Ser (7242A > G), were detected in BRCA2, whereas no such variant could be identified in BRCA1. We investigated the impact of these variants on breast cancer risk in a large case–control study. However, both SNPs, BRCA2 Ser2414Ser (7242A > G) and Ser455Ser (1365A > G), showed no association with breast cancer risk. This indicates that these codon-usage-changing SNPs have no major impact on familial breast cancer risk.

Keywords

Breast cancer risk Case–control study Codon-usage BRCA1 BRCA2 

References

  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108. doi:10.3322/canjclin.55.2.74 CrossRefPubMedGoogle Scholar
  2. 2.
    Hopper JL (2001) Genetic epidemiology of female breast cancer. Semin Cancer Biol 11:367–374. doi:10.1006/scbi.2001.0392 CrossRefPubMedGoogle Scholar
  3. 3.
    Narod SA (2002) Modifiers of risk of hereditary breast and ovarian cancer. Nat Rev Cancer 2:113–123. doi:10.1038/nrc726 CrossRefPubMedGoogle Scholar
  4. 4.
    Czene K, Lichtenstein P, Hemminki K (2002) Environmental and heritable causes of cancer among 9.6 million individuals in the Swedish family-cancer database. Int J Cancer 99:260–266. doi:10.1002/ijc.10332 CrossRefPubMedGoogle Scholar
  5. 5.
    Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K (2000) Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343:78–85. doi:10.1056/NEJM200007133430201 CrossRefPubMedGoogle Scholar
  6. 6.
    Hemminki K, Rawal R, Chen B, Bermejo JL (2004) Genetic epidemiology of cancer: from families to heritable genes. Int J Cancer 111:944–950. doi:10.1002/ijc.20355 CrossRefPubMedGoogle Scholar
  7. 7.
    Pharoah PD, Day NE, Duffy S, Easton DF, Ponder BA (1997) Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer 7:800–809. doi:10.1002/(SICI)1097-0215(19970529)71:5<800::AID-IJC18>3.0.CO;2-B CrossRefGoogle Scholar
  8. 8.
    Meindl A (2002) Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int J Cancer 97:472–480. doi:10.1002/ijc.1626 CrossRefPubMedGoogle Scholar
  9. 9.
    Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71. doi:10.1126/science.7545954 CrossRefPubMedGoogle Scholar
  10. 10.
    Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789–792. doi:10.1038/378789a0 CrossRefPubMedGoogle Scholar
  11. 11.
    Easton DF, Deffenbaugh AM, Pruss D, Frye C, Wenstrup RJ, Allen-Brady K, Tavtigian SV, Monteiro AN, Iversen ES, Couch FJ et al (2007) A systematic genetic assessment of 1, 433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet 81:873–883. doi:10.1086/521032 CrossRefPubMedGoogle Scholar
  12. 12.
    Wooster R, Weber BL (2003) Breast and ovarian cancer. N Engl J Med 348:2339–2347. doi:10.1056/NEJMra012284 CrossRefPubMedGoogle Scholar
  13. 13.
    Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL (2002) Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94:1365–1372PubMedGoogle Scholar
  14. 14.
    Thompson D, Easton DF (2002) Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94:1358–1365PubMedGoogle Scholar
  15. 15.
    Hughes DJ (2008) Use of association studies to define genetic modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Fam Cancer 7:233–244. doi:10.1007/s10689-008-9181-0 CrossRefPubMedGoogle Scholar
  16. 16.
    Esashi F, Christ N, Gannon J, Liu Y, Hunt T, Jasin M, West SC (2005) CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair. Nature 434:598–604. doi:10.1038/nature03404 CrossRefPubMedGoogle Scholar
  17. 17.
    Rebbeck TR, Wang Y, Kantoff PW, Krithivas K, Neuhausen SL, Godwin AK, Daly MB, Narod SA, Brunet JS, Vesprini D et al (2001) Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res 61:5420–5424PubMedGoogle Scholar
  18. 18.
    Antoniou AC, Spurdle AB, Sinilnikova OM, Healey S, Pooley KA, Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N et al (2008) Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet 82:937–948. doi:10.1016/j.ajhg.2008.02.008 CrossRefPubMedGoogle Scholar
  19. 19.
    Duan R, Pak C, Jin P (2007) Single nucleotide polymorphism associated with mature miR-125a alters the processing of pri-miRNA. Hum Mol Genet 16:1124–1131. doi:10.1093/hmg/ddm062 CrossRefPubMedGoogle Scholar
  20. 20.
    Wang X, Tomso DJ, Liu X, Bell DA (2005) Single nucleotide polymorphism in transcriptional regulatory regions and expression of environmentally responsive genes. Toxicol Appl Pharmacol 207:84–90. doi:10.1016/j.taap.2004.09.024 CrossRefPubMedGoogle Scholar
  21. 21.
    GuhaThakurta D, Xie T, Anand M, Edwards SW, Li G, Wang SS, Schadt EE (2006) Cis-regulatory variations: a study of SNPs around genes showing cis-linkage in segregating mouse populations. BMC Genomics 7:235. doi:10.1186/1471-2164-7-235 CrossRefPubMedGoogle Scholar
  22. 22.
    Yang R, Frank B, Hemminki K, Bartram CR, Wappenschmidt B, Sutter C, Kiechle M, Bugert P, Schmutzler RK, Arnold N et al (2008) SNPs in ultraconserved elements and familial breast cancer risk. Carcinogenesis 29:351–355. doi:10.1093/carcin/bgm290 CrossRefPubMedGoogle Scholar
  23. 23.
    Fan JB, Chee MS, Gunderson KL (2006) Highly parallel genomic assays. Nat Rev Genet 7:632–644. doi:10.1038/nrg1901 CrossRefPubMedGoogle Scholar
  24. 24.
    Kiyohara C, Yoshimasu K (2007) Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: a meta-analysis. Int J Med Sci 4:59–71PubMedGoogle Scholar
  25. 25.
    Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM (2007) A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science 315:525–528. doi:10.1126/science.1135308 CrossRefPubMedGoogle Scholar
  26. 26.
    Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM (2007) Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res 67:9609–9612. doi:10.1158/0008-5472.CAN-07-2377 CrossRefPubMedGoogle Scholar
  27. 27.
    Jamroziak K, Balcerczak E, Smolewski P, Robey RW, Cebula B, Panczyk M, Kowalczyk M, Szmigielska-Kaplon A, Mirowski M, Bates SE et al (2006) MDR1 (ABCB1) gene polymorphism C3435T is associated with P-glycoprotein activity in B-cell chronic lymphocytic leukemia. Pharmacol Rep 58:720–728PubMedGoogle Scholar
  28. 28.
    Liou YJ, Wang YC, Chen JY, Chen ML, Chen TT, Bai YM, Lin CC, Liao DL, Lai IC (2008) The coding-synonymous polymorphism rs1045280 (Ser280Ser) in beta-arrestin 2 (ARRB2) gene is associated with tardive dyskinesia in Chinese patients with schizophrenia. Eur J Neurol 15:1406–1408. doi:10.1111/j.1468-1331.2008.02316.x CrossRefPubMedGoogle Scholar
  29. 29.
    Knobe KE, Sjorin E, Ljung RC (2008) Why does the mutation G17736A/Val107Val (silent) in the F9 gene cause mild haemophilia B in five Swedish families? Haemophilia 14:723–728. doi:10.1111/j.1365-2516.2008.01753.x CrossRefPubMedGoogle Scholar
  30. 30.
    Komar AA (2007) Genetics SNPs, silent but not invisible. Science 315:466–467. doi:10.1126/science.1138239 CrossRefPubMedGoogle Scholar
  31. 31.
    Brunak S, Engelbrecht J (1996) Protein structure and the sequential structure of mRNA: alpha-helix and beta-sheet signals at the nucleotide level. Proteins 25:237–252. doi:10.1002/(SICI)1097-0134(199606)25:2<237::AID-PROT9>3.3.CO;2-Y CrossRefPubMedGoogle Scholar
  32. 32.
    Gupta SK, Majumdar S, Bhattacharya TK, Ghosh TC (2000) Studies on the relationships between the synonymous codon usage and protein secondary structural units. Biochem Biophys Res Commun 269:692–696. doi:10.1006/bbrc.2000.2351 CrossRefPubMedGoogle Scholar
  33. 33.
    Cortazzo P, Cervenansky C, Marin M, Reiss C, Ehrlich R, Deana A (2002) Silent mutations affect in vivo protein folding in Escherichia coli. Biochem Biophys Res Commun 293:537–541. doi:10.1016/S0006-291X(02)00226-7 CrossRefPubMedGoogle Scholar
  34. 34.
    Epstein RJ, Lin K, Tan TW (2000) A functional significance for codon third bases. Gene 245:291–298. doi:10.1016/S0378-1119(00)00042-1 CrossRefPubMedGoogle Scholar
  35. 35.
    Powell JR, Moriyama EN (1997) Evolution of codon usage bias in Drosophila. Proc Natl Acad Sci USA 94:7784–7790. doi:10.1073/pnas.94.15.7784 CrossRefPubMedGoogle Scholar
  36. 36.
    Capon F, Allen MH, Ameen M, Burden AD, Tillman D, Barker JN, Trembath RC (2004) A synonymous SNP of the corneodesmosin gene leads to increased mRNA stability and demonstrates association with psoriasis across diverse ethnic groups. Hum Mol Genet 13:2361–2368. doi:10.1093/hmg/ddh273 CrossRefPubMedGoogle Scholar
  37. 37.
    Nielsen KB, Sorensen S, Cartegni L, Corydon TJ, Doktor TK, Schroeder LD, Reinert LS, Elpeleg O, Krainer AR, Gregersen N et al (2007) Seemingly neutral polymorphic variants may confer immunity to splicing-inactivating mutations: a synonymous SNP in exon 5 of MCAD protects from deleterious mutations in a flanking exonic splicing enhancer. Am J Hum Genet 80:416–432. doi:10.1086/511992 CrossRefPubMedGoogle Scholar
  38. 38.
    Burwinkel B, Wirtenberger M, Klaes R, Schmutzler RK, Grzybowska E, Forsti A, Frank B, Bermejo JL, Bugert P, Wappenschmidt B et al (2005) Association of NCOA3 polymorphisms with breast cancer risk. Clin Cancer Res 11:2169–2174. doi:10.1158/1078-0432.CCR-04-1621 CrossRefPubMedGoogle Scholar
  39. 39.
    Dupont WD, Plummer WD Jr (1998) Power and sample size calculations for studies involving linear regression. Control Clin Trials 19:589–601. doi:10.1016/S0197-2456(98)00037-3 CrossRefPubMedGoogle Scholar
  40. 40.
    Loizidou M, Marcou Y, Anastasiadou V, Newbold R, Hadjisavvas A, Kyriacou K (2007) Contribution of BRCA1 and BRCA2 germline mutations to the incidence of early-onset breast cancer in Cyprus. Clin Genet 71:165–170. doi:10.1111/j.1399-0004.2007.00747.x CrossRefPubMedGoogle Scholar
  41. 41.
    Fackenthal JD, Olopade OI (2007) Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 7:937–948. doi:10.1038/nrc2054 CrossRefPubMedGoogle Scholar
  42. 42.
    Hogervorst FB, Nederlof PM, Gille JJ, McElgunn CJ, Grippeling M, Pruntel R, Regnerus R, van Welsem T, van Spaendonk R, Menko FH et al (2003) Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res 63:1449–1453PubMedGoogle Scholar
  43. 43.
    Anglian Breast Cancer Study Group (2000) Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 83:1301–1308. doi:10.1054/bjoc.2000.1407 CrossRefGoogle Scholar
  44. 44.
    Roa BB, Boyd AA, Volcik K, Richards CS (1996) Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14:185–187. doi:10.1038/ng1096-185 CrossRefPubMedGoogle Scholar
  45. 45.
    Palli D, Falchetti M, Masala G, Lupi R, Sera F, Saieva C, D’Amico C, Ceroti M, Rizzolo P, Caligo MA et al (2007) Association between the BRCA2 N372H variant and male breast cancer risk: a population-based case–control study in Tuscany Central Italy. BMC Cancer 7:170. doi:10.1186/1471-2407-7-170 CrossRefPubMedGoogle Scholar
  46. 46.
    Johnson N, Fletcher O, Palles C, Rudd M, Webb E, Sellick G, s Silva I, McCormack V, Gibson L, Fraser A et al (2007) Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. Hum Mol Genet 16:1051–1057. doi:10.1093/hmg/ddm050 CrossRefPubMedGoogle Scholar
  47. 47.
    Freedman ML, Penney KL, Stram DO, Le Marchand L, Hirschhorn JN, Kolonel LN, Altshuler D, Henderson BE, Haiman CA (2004) Common variation in BRCA2 and breast cancer risk: a haplotype-based analysis in the Multiethnic Cohort. Hum Mol Genet 13:2431–2441. doi:10.1093/hmg/ddh270 CrossRefPubMedGoogle Scholar
  48. 48.
    Houlston RS, Peto J (2003) The future of association studies of common cancers. Hum Genet 112:434–435PubMedGoogle Scholar
  49. 49.
    Antoniou AC, Easton DF (2003) Polygenic inheritance of breast cancer: implications for design of association studies. Genet Epidemiol 25:190–202. doi:10.1002/gepi.10261 CrossRefPubMedGoogle Scholar
  50. 50.
    Schattner P, Diekhans M (2006) Regions of extreme synonymous codon selection in mammalian genes. Nucleic Acids Res 34:1700–1710. doi:10.1093/nar/gkl095 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2009

Authors and Affiliations

  • Rongxi Yang
    • 1
    • 2
  • Bowang Chen
    • 3
  • Kari Hemminki
    • 3
    • 4
  • Barbara Wappenschmidt
    • 5
    • 6
  • Christoph Engel
    • 7
  • Christian Sutter
    • 8
  • Nina Ditsch
    • 9
  • Bernhard H. F. Weber
    • 10
  • Dieter Niederacher
    • 11
  • Norbert Arnold
    • 12
  • Alfons Meindl
    • 13
  • Claus R. Bartram
    • 8
  • Rita K. Schmutzler
    • 5
    • 6
  • Barbara Burwinkel
    • 1
    • 2
  1. 1.Helmholtz-University Group Molecular EpidemiologyGerman Cancer Research Center (DKFZ)HeidelbergGermany
  2. 2.Division Molecular Biology of Breast Cancer, Department of Gynecology and ObstetricsUniversity of HeidelbergHeidelbergGermany
  3. 3.Division of Molecular Genetic EpidemiologyGerman Cancer Research Center (DKFZ)HeidelbergGermany
  4. 4.Department of Biosciences at NovumKarolinska InstituteHuddingeSweden
  5. 5.Division of Molecular Gynaeco-Oncology, Department of Gynaecology and ObstetricsClinical Center University of CologneKölnGermany
  6. 6.Center of Molecular Medicine Cologne (CMMC)University Hospital of CologneKölnGermany
  7. 7.Department of Medical Informatics, Statistics and EpidemiologyUniversity of LeipzigLeipzigGermany
  8. 8.Institute of Human GeneticsUniversity of HeidelbergHeidelbergGermany
  9. 9.Department for Obstetrics and GynaecologyLudwig Maximilians UniversitätMunichGermany
  10. 10.Institute of Human GeneticsUniversity of RegensburgRegensburgGermany
  11. 11.Division of Molecular Genetics, Department of Gynaecology and ObstetricsClinical Center University of DüsseldorfDüsseldorfGermany
  12. 12.Division of Oncology, Department of Gynaecology and ObstetricsUniversity Hospital Schleswig–HolsteinKielGermany
  13. 13.Department of Gynaecology and Obstetrics, Klinikum rechts der IsarTechnical University of MunichMunichGermany

Personalised recommendations